Ovarian Cancer

On this page

Ovarian Cancer Basics - Ovary's Enemies

  • Types: Epithelial (most common, ~90%; serous, mucinous, endometrioid, clear cell), Germ cell (younger patients), Sex-cord stromal.
  • Epidemiology:
    • Peak incidence: 50-70 years.
    • Highest mortality among gynecologic cancers.
  • Risk Factors (↑ Risk):
    • Age (postmenopausal).
    • Nulliparity, infertility, uninterrupted ovulation.
    • Early menarche (<12 yrs), late menopause (>55 yrs).
    • Family Hx: BRCA1/BRCA2 mutations, Lynch syndrome (HNPCC).
    • Personal Hx of breast, colon, or endometrial cancer.
    • Endometriosis.
  • Protective Factors (↓ Risk):
    • Multiparity.
    • Oral Contraceptive Pills (OCPs) use (≥5 years ↓ risk by ~50%).
    • Breastfeeding.
    • Tubal ligation, salpingectomy, hysterectomy.

⭐ BRCA1 mutation carriers have a ~40-50% lifetime risk of ovarian cancer; BRCA2 carriers ~15-25%.

BRCA2 Pedigree with Ovarian, Breast, Pancreatic Cancer

Pathology & Staging - Rogue Cell Roundup

  • Pathological Types:
    • Epithelial (~90%): Serous (MC), Mucinous, Endometrioid, Clear Cell.
    • Germ Cell (younger): Dysgerminoma, Yolk Sac (↑AFP), Teratoma.
    • Sex Cord-Stromal: Granulosa (↑estrogen, Call-Exner), Fibroma (Meigs' syndrome).
  • FIGO Staging (Simplified):
    • Stage I: Limited to ovaries
      • IA: One ovary
      • IB: Both ovaries
      • IC: Rupture/surface tumor/positive cytology
    • Stage II: Pelvic extension
      • IIA: Uterus/fallopian tubes
      • IIB: Other pelvic tissues
    • Stage III: Peritoneal implants outside pelvis / regional LN+
      • IIIC: Macroscopic peritoneal mets >2 cm
    • Stage IV: Distant metastases
      • IVA: Pleural effusion (positive cytology)
      • IVB: Parenchymal/extra-abdominal mets

⭐ CA-125: key marker for epithelial ovarian cancer; monitors treatment response/recurrence, not for screening.

  • Symptoms (Often Vague - "Silent Killer"):

    • Abdominal bloating/distension, pelvic/abdominal pain.
    • Early satiety, changes in bowel habits (constipation/diarrhea).
    • Urinary urgency/frequency.
    • 📌 Mnemonic BEAT: Bloating, Eating difficulty (early satiety), Abdominal/pelvic pain, Trouble with bladder.
  • Signs: Palpable adnexal mass (often bilateral), ascites, pleural effusion, weight loss.

  • Diagnostic Approach:

    • Pelvic Exam: Bimanual exam to assess adnexa.
    • Imaging:
      • Transvaginal Ultrasound (TVS): Initial modality of choice; assesses mass characteristics (cystic, solid, septations, papillary projections).
      • CT Abdomen/Pelvis (with contrast): For staging, detecting metastases.
    • Tumor Markers:
      • CA-125: Elevated in ~80% epithelial ovarian cancer (EOC). Thresholds: >35 U/mL (postmenopausal), >200 U/mL (premenopausal) concerning. Not specific.
      • HE4 (Human Epididymis Protein 4): More specific than CA-125, especially premenopausal.
      • ROMA (Risk of Ovarian Malignancy Algorithm): Combines CA-125, HE4, menopausal status.
      • Germ cell tumors: AFP, β-hCG, LDH.
      • Sex cord-stromal tumors: Inhibin A & B, AMH.
    • Biopsy: Definitive diagnosis; usually obtained during surgical staging (laparotomy/laparoscopy). Image-guided biopsy for advanced/recurrent disease.

Transvaginal ultrasound of complex ovarian mass

⭐ CA-125 is the most commonly used tumor marker for epithelial ovarian cancer; however, it can be elevated in numerous benign conditions (e.g., endometriosis, fibroids, PID, pregnancy) and other malignancies, limiting its specificity as a screening tool, especially in premenopausal women. Its primary utility is in monitoring treatment response and detecting recurrence in diagnosed cases.

Management & Prognosis - Battle Plan & Beyond

  • Core Strategy: Surgery & Chemotherapy are cornerstones.
    • Surgery: Comprehensive staging & maximal cytoreduction (aim R0: no visible disease).
    • Chemo: Carboplatin + Paclitaxel (IV/IP). Neoadjuvant (NACT) for advanced/unresectable.
  • Targeted Therapy:
    • PARP inhibitors (e.g., Olaparib): For BRCAm/HRD+ or platinum-sensitive recurrence.
    • Bevacizumab (anti-VEGF): With chemo & as maintenance.
  • Recurrence: Platinum-sensitive vs. resistant dictates therapy.
  • Prognosis: Stage, grade, residual disease critical. CA-125 for monitoring.
    • 5-yr survival: Stage I >90%; Stage III ~30-40%; Stage IV <20%.
  • Follow-up: Regular exams, CA-125, imaging as indicated.

⭐ Optimal cytoreduction to R0 (no macroscopic residual disease) is the most crucial modifiable prognostic factor in advanced ovarian cancer.

High‑Yield Points - ⚡ Biggest Takeaways

  • Epithelial tumors (esp. serous cystadenocarcinoma) are most common.
  • Key risk: BRCA1/2 mutations; Protective: OCPs, multiparity.
  • Often presents late with vague abdominal symptoms, ascites.
  • CA-125 for monitoring response, not for general screening.
  • Management: Surgical staging/cytoreduction + platinum-based chemotherapy.
  • Germ cell tumors (younger patients): Dysgerminoma (LDH), Yolk sac (AFP).
  • Granulosa cell tumors: Estrogenic, Call-Exner bodies, inhibin_A & B_

Practice Questions: Ovarian Cancer

Test your understanding with these related questions

Which of the following screening methods is NOT effective for early detection of cancer in asymptomatic women?

1 of 5

Flashcards: Ovarian Cancer

1/10

_____ mutation carriers have increased risk for serous adenocarcinoma of the ovary and fallopian tube

TAP TO REVEAL ANSWER

_____ mutation carriers have increased risk for serous adenocarcinoma of the ovary and fallopian tube

BRCA1

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial